New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - rivaroxaban 20mg - film coated tablet - 20 mg - active: rivaroxaban 20mg excipient: colloidal silicon dioxide croscarmellose sodium iron oxide red lactose macrogol 8000 magnesium stearate poloxamer 407 polyvinyl alcohol purified talc purified water titanium dioxide - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - ezetimibe 10mg - tablet - 10 mg - active: ezetimibe 10mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate polysorbate 80 sodium laurilsulfate tolpovidone i 131 - primary hypercholesterolaemia ezetimibe, administered with an hmg-coa reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), lowdensity lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and triglycerides (tg) and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia. homozygous familial hypercholesterolaemia (hofh) ezetimibe, administered with a statin, is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - solifenacin succinate 10mg - film coated tablet - 10 mg - active: solifenacin succinate 10mg excipient: croscarmellose sodium hyprolose iron oxide red lactose macrogols magnesium stearate polyvinyl alcohol purified talc purified water titanium dioxide - for the treatment of an unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - solifenacin succinate 5mg - film coated tablet - 5 mg - active: solifenacin succinate 5mg excipient: croscarmellose sodium hyprolose iron oxide yellow lactose macrogols magnesium stearate polyvinyl alcohol purified talc purified water titanium dioxide - for the treatment of an unstable bladder with symptoms of increased urinary urgency, frequent micturition, and/or urge incontinence.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - dasatinib 100mg - film coated tablet - 100 mg - active: dasatinib 100mg excipient: colloidal silicon dioxide croscarmellose sodium ethylcellulose hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triethyl citrate - dasatinib is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). dasatinib is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - dasatinib 20mg - film coated tablet - 20 mg - active: dasatinib 20mg excipient: colloidal silicon dioxide croscarmellose sodium ethylcellulose hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triethyl citrate - dasatinib is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). dasatinib is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - dasatinib 50mg - film coated tablet - 50 mg - active: dasatinib 50mg excipient: colloidal silicon dioxide croscarmellose sodium ethylcellulose hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triethyl citrate - dasatinib is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). dasatinib is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - dasatinib 70mg - film coated tablet - 70 mg - active: dasatinib 70mg excipient: colloidal silicon dioxide croscarmellose sodium ethylcellulose hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified water titanium dioxide triethyl citrate - dasatinib is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). dasatinib is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - diclofenac sodium 100mg - modified release tablet - 100 mg - active: diclofenac sodium 100mg excipient: dextrates hyetellose hypromellose iron oxide red iron oxide yellow macrogol 3350 magnesium stearate microcrystalline cellulose titanium dioxide - diclofenac is used for the relief of moderate pain and inflammation in: - rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. - painful post-operative inflammation and swelling (including dental and orthopaedic procedures). - painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. - in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.

New Zealand - English - Medsafe (Medicines Safety Authority)

clinect nz pty limited - diclofenac sodium 75mg - modified release tablet - 75 mg - active: diclofenac sodium 75mg excipient: carnauba wax dextrates hyetellose hypromellose iron oxide red macrogol 3350 magnesium stearate microcrystalline cellulose purified water titanium dioxide - diclofenac is used for the relief of moderate pain and inflammation in: - rheumatic disorders: e.g. ankylosing spondylitis, osteoarthritis, and rheumatoid arthritis including juvenile rheumatoid arthritis, painful syndromes of the vertebral column, nonarticular rheumatism. - painful post-operative inflammation and swelling (including dental and orthopaedic procedures). - painful or inflammatory gynaecological conditions e.g. primary dysmenorrhoea. - in keeping with general therapeutic principles, the underlying disease should be treated with basic therapy, as appropriate. diclofenac provides symptomatic relief but has not been shown to halt or reverse the underlying disease process. fever alone is not an indication.